SciELO - Scientific Electronic Library Online

vol.19 número2Diferencias de género en la presentación clínica y angiográfica del Síndrome Coronario AgudoCaracterísticas clínico-epidemiológicas de la COVID-19 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO


Revista Habanera de Ciencias Médicas

versión On-line ISSN 1729-519X


GIRALT-HERRERA, Alejandro; ROJAS-VELAZQUEZ, Jesús Miguel  y  LEIVA-ENRIQUEZ, Jessica. Relationship between COVID-19 and Hypertension. Rev haban cienc méd [online]. 2020, vol.19, n.2, e3246.  Epub 22-Abr-2020. ISSN 1729-519X.


The first three months of 2020 have been influenced by the spreading of a pandemic caused by the SARS-coronavirus 2, which causes COVID-19 infection that in some cases is associated with acute respiratory distress syndrome.


To identify the relationship between COVID-19 and hypertension.

Material and Methods:

A bibliographic review was carried out using database search engines. In addition, reference literature in Cardiology was used as well as information from official government websites such as WHO/PAHO and other scientific societies.


Coronaviruses enter into target cells through a spike S protein, whose S1 surface unit is coupled to the angiotensin-converting enzyme 2 as a receptor. In the different revised series, the clear relationship between the history of arterial hypertension and the unfavorable evolution is observed in patients with COVID-19. In an extensive literature search, there is no scientific evidence for discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hypertensive patients with COVID-19.


The angiotensin-converting enzyme acts as a SARS-CoV2 receptor. Hypertensive individuals have a less favorable evolution course of the condition caused by this virus. Discontinuation of treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers is not advisable in hypertensive patients with COVID-19.

Palabras clave : COVID-19; SARS-CoV 2; 2019-Ncov; SARS; coronavirus; hypertension.

        · resumen en Español     · texto en Español     · Español ( pdf )